Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease

Area of Science:

• Pediatrics
• Rheumatology
• Immunology

Background:

• Kawasaki disease is a primary cause of acquired heart disease in children.
• Intravenous immunoglobulin (IVIG) is the standard treatment to prevent cardiovascular sequelae.
• Current clinical guidelines for IVIG use in Kawasaki disease are lacking.

Purpose of the Study:

• To establish a consensus on the clinical application strategy of IVIG for Kawasaki disease in children.
• To provide recommendations for preventing and managing adverse reactions associated with IVIG therapy.
• To synthesize current research and expert opinions for evidence-based guidelines.

Main Methods:

• Literature review of IVIG application in Kawasaki disease, both domestic and international.
• Analysis of existing diagnosis and treatment guidelines for Kawasaki disease.
• Incorporation of expert consensus and clinical experience.

Main Results:

• The consensus outlines specific recommendations for IVIG dosing and administration timing.
• Strategies for monitoring and managing potential adverse events are detailed.
• Emphasis is placed on individualized treatment approaches based on patient factors.

Conclusions:

• This consensus provides a framework for optimizing IVIG therapy in pediatric Kawasaki disease.
• Adherence to these guidelines can improve treatment efficacy and patient safety.
• Further research is needed to refine IVIG protocols and address remaining clinical questions.